Meeting
2022 ASCO Annual Meeting
Disparity between Ki67 measurements and tumor gene expression tests in patients with hormone-sensitive early breast cancer from the OPTIMA preliminary trial.
Authors
Robert C. Stein
National Institute for Health Research University College London Hospitals Biomedical Research Centre, London, United Kingdom
Robert C. Stein , Andrea Marshall , Jane Bayani , Andreas Makris , Iain R. MacPherson , Luke Hughes-Davies , Monika Sobol , Tammy Piper , Georgina Dotchin , Helen Higgins , Abeer Shaaban , Sarah E. Pinder , Janet Dunn , John Bartlett
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Biologic Correlates
Clinical Trial Registration Number
ISRCTN42400492
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 567)
DOI
10.1200/JCO.2022.40.16_suppl.567
Abstract #
567
Poster Bd #
339
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
OPTIMA prelim: Optimal personalized treatment of early breast cancer using multiparameter tests.
First Author: Rob Stein
Poster
2022 ASCO Annual Meeting
Adjuvant abemaciclib for high-risk early breast cancer (EBC): Factors increasing the rate of treatment discontinuations in monarchE.
First Author: Sara M. Tolaney
First Author: Oleg Gluz
Poster
2021 ASCO Annual Meeting
Cost-effectiveness of the Oncotype DX Breast Recurrence Score test in postmenopausal women with node-positive early breast cancer based on the RxPONDER trial.
First Author: Vladislav Berdunov